Home Clinical trials For patients Ovary BGOG-ov76/GLORIOSA

BGOG-ov76/GLORIOSA

Randomized, Multicenter, Open-label, Phase 3 Study of Mirvetuximab Soravtansine in Combination With Bevacizumab Versus Bevacizumab Alone as Maintenance Therapy for Patients With FRα-high Recurrent Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers Who Have Not Progressed After Second Line Platinum-based Chemotherapy Plus Bevacizumab (GLORIOSA)

Open
Trial drug
Mirvetuximab soravtansin, Bevacizumab
Grade
High grade
Prior lines
1
Biomarkers
⍺FR
Histology
Serous
Platin
Platinum sensitive
Phase
III

Treatment

This study consists of two different treatment options: 

  • Mirvetuximab soravtansine + Bevacizumab
  • Bevacizumab

Both Mirvetuximab soravtansine and Bevacizumab will be administered intravenously every three weeks.

To be eligible for this trial you will need sufficient amounts of a certain protein (α folate receptor (αFR)) on your tumor cells.
You will be randomly allocated to one of both treatment groups.

Treatment duration

The treatment can continue until disease progression, unacceptable toxicities or until you decide to stop.

Contact

To be able to give you the best information and care we do not give medical advice via mail. We kindly ask you to make an appointment via lgog@uzleuven.be.